
    
      A randomized, double-blinded, placebo-controlled, parallel, multicenter, phase 2b study to
      evaluate the efficacy and safety of CVI-HBV-002 in patients with chronic hepatitis B taking
      Tenofovir disoproxil fumarate/Tenofovir disoproxil
    
  